Reputations for Sale ? BMJ-BBC-Panorama-Seroxat/ Paxil
BBC-Panorama–third in a series: The Secrets of Seroxat. "In the interests of patients and professional integrity" is to show those who have sold their reputations "intolerance and exposure."
BBC-Panorama–third in a series: The Secrets of Seroxat. "In the interests of patients and professional integrity" is to show those who have sold their reputations "intolerance and exposure."
"Daily use of SSRIs was also associated with a four per cent reduction in bone mineral density of the hip and 2.4 per cent of the lower spine, the study found."
The video, "Zyprexa Drug Rep," was posted on YouTube on Dec. 18. When AHRP publicized its (Jan 4) there were something on the order of 38 hits. Since the Infomail was posted on the AHRP website and blog (http://ahrp.blogspot.com the number has reached: 1,429.
Only if one assumes that the FDA sees the drug industry as its client can some sense be made of December 13th meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee in Silver Springs, Maryland.
NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation."
Expert Scientists, Psychiatrists, a Primary Care Physician, a Leading Attorney, will shed light on FDA’s Review of selected data Re: Antidepressants and Adult Suicidality One day prior to FDA’s Advisory Committee Hearing, December 13.
Dr. Wolpe’s Accusations and Dr. Healy’s Response —–Original Message—– From: Paul Root Wolpe Sent: Tuesday, October 28, 2003 4:30 PM To: VERACARE Subject: Re: Ethics of U Penn surgical “drug implant” experiment Vera, We will have to agree to disagree, so this will be my last email on this. A…
Psychopharmacology in Turmoil: David Healy, MD Presentation Columbia + Debate Dr. Joseph Coyne, Ph.D Fri, 9 Dec 2005 Recent reports describing a determined effort to pathologize US infants and toddlers who are being declared to suffer from “severe mental disorders”–the latest, most aggressively marketed diagnosis for children is Bipolar disorder,…
Antidepressant Makers Withhold Data on Children – Washington Post Thu, 29 Jan 2004 A front page article in The Washington Post addresses the key issue undermining public health and safety. Drug companies conceal unfavorable clinical trial findings: the tests failed to demonstrate that antidepressants are either safe or beneficial for…
Lead author of JAMA article rethinks positive Zoloft report – Guardian Wed, 1 Oct 2003 In August 2003, the Sertraline Pediatric Study Group reported: “Sertraline-treated patients experienced statistically significantly greater improvement than placebo.” Their report was published in the authoritative Journal of the American Medical Association (JAMA). The authors claimed…
Bioethics Debate: Ethics of U Penn Surgical “Drug Implant” Experiment This debate between AHRP President, Vera Sharav and Bioethicist, Paul Root Volpe, Ph.D., University of Pennsylvania, was prompted by an October 7 infomail. The reasons for AHRP’s opposition to drug implants for psychiatric patients are explained here: https://ahrp.org/ahrpspeaks/drugimplant1103.php —–Original Message—–…
What the FDA Isn’t Telling You – SLATE Date: Tue, 27 Sep 2005 Writing in SLATE, Jeanne Lenzer has uncovered evidence demonstrating FDA culpability in helping drug manufacturers conceal vital, life-saving information from the public. In this case, undisclosed suicides in clinical trials testing Eli Lilly’s drug, duloxetine (trade names:…